GlassScriptPhysician profile
Donald H Kim
NPI 1821035916
$2,645.62
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $597 · 2021: $457 · 2022: $101 · 2023: $22.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $702.89 | 2019-2023 | Relistor |
| Daiichi Sankyo INC. | $229.42 | 2019 | |
| Pfizer INC. | $201.64 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $195.48 | 2020-2021 | |
| Abbott Laboratories | $145.50 | 2019 | |
| Redhill Biopharma INC. | $138.86 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $129.37 | 2019-2020 | |
| Pacira Therapeutics, INC. | $127.80 | 2019 | |
| Medtronic USA, INC. | $111.53 | 2019 | |
| Tersera Therapeutics LLC | $87.95 | 2019-2020 | |
| Shionogi INC | $73.33 | 2019 | |
| Boston Scientific Corporation | $70.99 | 2020 | |
| Eisai INC. | $53.42 | 2020 | |
| Scilex Pharmaceuticals INC. | $52.59 | 2019 | |
| Amgen INC. | $52.51 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $48.36 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.65 | 2019 | |
| Assertio Therapeutics, INC. | $29.00 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $28.46 | 2019 | |
| Collegium Pharmaceutical, INC. | $26.82 | 2019 | |
| Allergan, INC. | $26.14 | 2020 | |
| Sentynl Therapeutics, INC. | $25.56 | 2019 | |
| Abbvie INC. | $21.01 | 2021 | |
| Forte Bio-Pharma LLC | $15.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.